Information Provided By: 
Fly News Breaks for January 22, 2020
TARA
Jan 22, 2020 | 07:08 EDT
Ladenburg Thalmann analyst Matthew Kaplan initiated coverage of Artara Therapeutics with a Buy rating and $45 price target. The company has two late-stage clinical assets in development for the treatment of lymphatic malformations and intestinal failure associated liver disease, Kaplan tells investors in a research note. The analyst says ArTara's management team has extensive experience in developing products in the rare disease space. He views the stock as an attractive investment opportunity.
News For TARA From the Last 2 Days
There are no results for your query TARA
